Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Abstract In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in an...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Laahn Foster, Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2025-10-01
Edice:Blood Cancer Journal
On-line přístup:https://doi.org/10.1038/s41408-025-01355-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky